Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Chronic Kidney Disease
In brief
The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).
Key facts
- Study ID
- NCT05928936
- Run by
- Emory University
- People needed
- 156
- Starts
- 2022-11-11
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2025-10-21
Who can join
Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- patients with CKD (Stages III and IV), kidney transplant recipients with varying degrees of kidney function, or persons without kidney disease as matched study controls
- sedentary and do not regularly exercise (defined as exercising < 20 minutes twice per week)
- CKD patients must have stable renal function (no greater than a decline of estimated glomerular filtration (eGFR) of 1 cc/min/1.73 m2 per month over the prior 6 months) and baseline serum bicarbonate 22-24 mmol/L
- comorbid hypertension
You may not qualify if…
- severe CKD (eGFR<15 cc/min)
- metabolic alkalosis
- current treatment with bicarbonate
- ongoing drug or alcohol abuse
- diabetic neuropathy, autonomic dysfunction
- any serious disease that might influence survival
- anemia with hemoglobin <10 g/dL
- clinical evidence of heart failure
- volume overload or ejection fraction below 45%
- symptomatic heart disease by EKG, stress test, and/or history
- treatment with central α-agonists (clonidine)
- myocardial infarction or cerebrovascular accident within the past six months
- uncontrolled hypertension (BP>170/100 mm Hg)
- low BP<100/50 mm Hg
- surgery within the past 3 months
- pregnancy or plans to become pregnant
- inability to exercise on a stationary bicycle
- contraindication to temporary withdrawal of α- and β-blockers
- peripheral arterial disease
- class 3 obesity (BMI>40)
- hypo- or hyperkalemia (K<3.5meq/L, K>5.0 meq/L)
- current use of immunosuppressive medications (including but not limited to steroids, cyclophosphamide, calcineurin inhibitors, mycophenolate, biologics, methotrexate, etc)
- arteriovenous (AV) fistula/graft
- any contraindication to MR scanning including cardiac pacemaker, cochlear implants, neurostimulators, implanted devices with metal, any metal in the body that could pose a hazard during scanning, history of claustrophobia
Where it is running
- Emory Clinic — Atlanta, Georgia, United States (enrolling)
- Atlanta VA Medical Center — Decatur, Georgia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.